NeuroScios
 | |
| | |
| NeuroScios GmbH | |
|---|---|
| Industry | Research |
| Founded | 2013 |
| Number of employees | 11-50 |
Contents
About Us
With 30 years of experience in CNS drug development we may offer you the fastest track from molecule to clinic. As a contract research organization we
-Support the development of new treatments for CNS diseases
-Alzheimer’s disease -Parkinson’s disease
-Orphan neurodegenerative disorders
-Cerebrovascular diseases
-Psychiatric diseases
-Accelerate the drug/ treatment development by our profound knowledge of the requirements
-Pharmacology
-ADME
-Toxicology
-Regulatory issues (IND/ CTA)
- Clinical trials
-Optimize the chance of success, by knowing
-the most suitable preclinical models
-the most experienced and reliable service providers
-the competitive environment
- Support our clients in the best way by
-Designing most efficient individualized development plan
-Providing an outstanding network of KOLs in different fields of CNS diseases
- Fastest reaction time
-Competitive pricing
- International experience for more than 30 years
Services
- Consulting
- Clinical Neuroscience
- CNS Clinical Research
- Pharmacovigilance
Controversies
Top 5 Recent Tweets
| Date | Author | Comment |
|---|---|---|
| October 25, 2022 | DrSenthil5 | Manfred Windisch is CEO of NeuroScios—Neuroscience Optimized Solutions. NeuroScios specializes in consulting for dr… https://t.co/SD3v1oSaDV |
Top 5 Recent News Headlines
Top 5 Lifetime Tweets
Top 5 Lifetime News Headlines
Top Authors
Verification history
2,716 days ago- View all verifications
